
|Videos|May 13, 2014
Combining Immunotherapies
Author(s)Jedd D. Wolchok, MD, PhD
Jedd D. Wolchok, MD, PhD, from Memorial Sloan Kettering Cancer Center, discusses ongoing research regarding combinations of immunotherapies.
Advertisement
Clinical Pearls
Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Lloyd J. Old Chair for Clinical Investigation, Memorial Sloan Kettering Cancer Center, discusses ongoing research regarding combinations of immunotherapies.
- Aphase III study led by MSKaims to compare nivolumab, ipilimumab, and the combination of the drugs in newly diagnosed patients with advanced melanoma.
- There remains a need to determine the benefits of concurrent combination therapies versus sequenced therapies.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















